Erythrocyte and reticulocyte indices in iron deficiency in chronic kidney disease: comparison of two methods

References

• Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end‐stage renal disease with recombinant human erythropoietin: results of phase I and II clinical trial. N Engl J Med 1987; 316: 73–8
   PubMed Web of Science ®Google Scholar
• Besarab A., Amin N., Ahsan M., Vogel S. E., Zazuwa G., Frinak S., Zazra J. J., Anandan J. V., Gupta A. Optimization of epoietin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530–8
   PubMed Web of Science ®Google Scholar
• Evans R. W., Rader B., Manninen D. L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. J Am Med Assoc 1990; 263: 825–30
   PubMed Web of Science ®Google Scholar
• Silverberg D. S., Blum M., Agbaria Z., Deutsch V., Irony M., Schwartz D., Baruch R., Yachnin T., Steinbruch S., Iaina A. The effect of i.v. iron alone or in combination with low‐dose erythropoietin in the rapid correction of anemia of chronic renale failure in the predialysis period. Clin Nephrol 2001; 55: 212–19
   PubMed Web of Science ®Google Scholar
• Fishbane S., Frei G. L., Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41–6
   PubMed Web of Science ®Google Scholar
• Macdougall I. C., Tucker B., Thompson J., Tomson C. R., Baker L. R., Raine A. E. A randomised controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694–9
   PubMed Web of Science ®Google Scholar
• Locatelli F., Aljama P., Barany P., Aljama P., Bárány P., Canaud B., Carrera F., Eckardt K. U., Hörl W. H., Macdougal I. C., Macleod A., Wiecek A., Cameron S., the European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transpl 2004; 19(Suppl 2)1–47
   PubMed Web of Science ®Google Scholar
• Thomas C., Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48: 1066–76
   PubMed Web of Science ®Google Scholar
• Tessitore N., Solero G. P., Lippi G., Bassi A., Faccini G. B., Bedogna V., Gammaro L., Brocco G., Restivo G., Bernich P., Lupo A., Maschio G. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transpl 2001; 16: 1416–23
   PubMed Web of Science ®Google Scholar
• Cullen P., Söffker J., Höpfl M., Bremer C., Schlaghecken R., Mehrens T., Assmann G., Schaefer R. M. Hypochromic red cells and reticulocyte content as markers of iron‐deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transpl 1999; 3: 659–65
   Web of Science ®Google Scholar
• Macdougall I. C. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of the hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transpl 1998; 13: 847–9
   PubMed Web of Science ®Google Scholar
• Fishbane S., Galgano C., Langley R. C., Jr., Canfield W., Maesaka J. K. Reticulocyte haemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997; 2: 217–22
   Web of Science ®Google Scholar
• Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring erythropoietic function. Crit Rev Clin Lab Sci 2000; 37: 93–130
   PubMed Web of Science ®Google Scholar
• Braun J., Lindner K., Schreiber M., Heidler R. A., Hörl W. H. Percentuage hypochromic red cells as a predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transpl 1997; 12: 1173–81
   PubMed Web of Science ®Google Scholar
• Sunder‐Plassmann G., Spitzauer S., Horl W. H. The dilemma of evaluating iron status in dialysis patients: limitation of available diagnostics procedures. Nephrol Dial Transpl 1998; 13: 850–1
   PubMed Web of Science ®Google Scholar
• Briggs C., Harrison P., Grant D., Staves J., MacHin S. J. New quantitative parameters on a recent introduced automated blood cell counter – the XE‐2100. Clin Lab Haematol 2000; 22: 345–50
   PubMedGoogle Scholar
• Buttarello M., Temporin V., Ceravolo R., Farina G., Bulian P. The new reticulocyte parameter (RET‐Y) of the Sysmex XE‐2100. Its use in the diagnosis and monitoring of posttreatment sideropenic anemia. Am J Clin Pathol 2004; 121: 489–95
   PubMed Web of Science ®Google Scholar
• Franks S., Linssen J., Messinger M., Thomas L. Potential utility of Ret‐Y in the diagnosis of iron‐restricted erythropoiesis. Clin Chem 2004; 50: 1240–2
   PubMed Web of Science ®Google Scholar
• Fishbane S., Shapiro W., Dutka P., Valenzuela O. F., Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60: 2406–11
   PubMed Web of Science ®Google Scholar
• Canals C., Remacha A. F., Sarda M. P., Piazuelo J. M., Royo M. T., Romero M. A. Clinical utility of the new Sysmex XE‐2100 parameter‐reticulocyte haemoglobin equivalent in the diagnosis of anemia. Haematologica 2001; 90: 1133–4
   Google Scholar
• Thomas L., Frank S., Messinger M., Linssen J., Thomé M., Thomas C. Reticulocyte haemoglobin measurement. Comparison of two methods in the diagnosis of iron‐restricted erythropoiesis. Clin Chem Lab Med 2005; 43: 1193–202
   PubMed Web of Science ®Google Scholar
• Frank S., Linssen J., Messinger M., Thomas L. Potential utility of RET‐Y in the diagnosis of iron‐restricted erythropoiesis. Clin Chem 2004; 50: 1240–2
   PubMed Web of Science ®Google Scholar
• Briggs C., Roger R., Thompson B., Machin S. J. New red cell parameters on the Sysmex XE‐2100 as potential markers of functional iron deficiency. Infus Ther Transfus Med 2001; 28: 256–62
   Google Scholar
• David O., Grillo A., Ceoloni B., Cavallo F., Podda G., Biancotti P. P., Bergamo D., Canavese C. Analysis of red cell parameters on the Sysmex XE2100 and ADVIA 120 in iron deficiency and in uraemic chronic disease. Scand J Clin Lab Invest 2006; 66: 113–20
   PubMed Web of Science ®Google Scholar